Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates
Zynex Inc. (ZYXI) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.10 per share a year ago.
Zynex sees pain management orders increase in Q3 following FDA approval
Zynex Inc (NASDAQ:ZYXI) announced its third-quarter 2024 financial and operational results highlighted by a 13% year-over-year increase in orders. The pain management device company reported net re...
Zynex Sets Third Quarter 2024 Earnings Call
ENGLEWOOD, Colo. , Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pa...
Zynex's strategic shifts set stage for long-term success, analysts say
Analysts expect Zynex Inc (NASDAQ:ZYXI) to return to stronger growth in 2025, driven by product diversification, sales force expansion, and upcoming product launches. The company's strategic initia...
Zynex CEO reflects on 28 years of medical device innovation - ICYMI
Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard recently sat down with Proactive to discuss the medical device company's innovative solutions and impressive growth trajectory. Sandgaard highlighted ...
Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.
Zynex to Present at the HC Wainwright Global Investment Conference
ENGLEWOOD, Colo. , Sept. 4, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pa...
Zynex pain management device TensWave achieves FDA clearance
Zynex Inc (NASDAQ:ZYXI) announced that its portable pain management device TensWave has achieved Food and Drug Administration (FDA) clearance. The prescription-only TensWave device aims to provide ...
Why Zynex Plunged Today
Zynex missed on second-quarter revenue and earnings, and guided down. However, some of the near-term weakness was by design, as the company is cutting costs.
Zynex Sets Second Quarter 2024 Earnings Call
ENGLEWOOD, Colo. , July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pa...
Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces
ENGLEWOOD, Colo. , July 11, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pa...
All You Need to Know About Zynex (ZYXI) Rating Upgrade to Buy
Zynex (ZYXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Zynex (ZYXI) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the lat...
Zynex (ZYXI) is an Incredible Growth Stock: 3 Reasons Why
Zynex (ZYXI) possesses solid growth attributes, which could help it handily outperform the market.
Are Investors Undervaluing Zynex (ZYXI) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the lat...
Related Companies